Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 8, November, p. 1263–1268

doi: 10.17219/acem/65823

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Antihypertensive treatment prescription in pediatric dialysis patients in Poland: A comparison between two nationwide studies 2003/2004–2013

Krzysztof Wróblewski1,A,B,C,D,E,F, Karolina Hincz2,B, Monika Miklaszewska3,B, Katarzyna Zachwieja3,B, Ryszard Wierciński4,B, Roman Stankiewicz5,B, Agnieszka Firszt-Adamczyk5,B, Jacek Zachwieja6,B, Halina Borzęcka7,B, Helena Ziółkowska8,B, Anna Medyńska9,B, Danuta Zwolińska9,B, Maria Szczepańska10,B, Małgorzata Stańczyk11,B,C, Ilona Zagożdżon12,B, Beata Leszczyńska8,B, Piotr Adamczyk10,B, Marcin Tkaczyk11,13,A,B,E,F

1 Department of Internal Medicine and Nephrodiabetology, Medical University of Lodz, Poland

2 Department of Gynecology and Perinatology, Polish Mothers Memorial Hospital Research Institute, Poland

3 Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Kraków, Poland

4 Department of Pediatrics and Nephrology, Medical University of Bialystok, Poland

5 Department of Pediatric Nephrology, Regional Hospital, Toruń, Poland

6 Department of Cardiology and Nephrology, Poznan University of Medical Sciences, Poland

7 Department of Pediatric Nephrology, Medical University of Lublin, Poland

8 Chair and Department of Pediatrics and Nephrology, Medical University of Warsaw, Poland

9 Department of Pediatric Nephrology, Wroclaw Medical University, Poland

10 Department of Nephrology and Dialysis, Medical University of Silesia, Zabrze, Poland

11 Department of Pediatrics, Immunology and Nephrology, Polish Mothers Memorial Hospital Research Institute, Poland

12 Department of Child and Adolescents’ Nephrology and Hypertension, Medical University of Gdańsk, Poland

13 Division of Didactics in Pediatrics, Medical University of Lodz, Poland


Background. Blood pressure in pediatric dialyzed patients is under poor control.
Objectives. The aim of the study was to assess the strategy and efficacy of antihypertensive drugs used for the treatment of hypertension in pediatric dialyzed patients in 2013 in comparison with the data collected in 2003/2004. The results have been viewed against present strategies of antihypertensive treatment in children. There is still limited data concerning the treatment of hypertension in dialyzed pediatric patients.
Material and Methods. The study embraced 10 of 12 pediatric dialysis units in Poland treating 59 pediatric patients (mean age – 132 months). Collected information included present antihypertensive treatment with regard to drug classes and the dose of antihypertensive agent. The treatment was regarded as effective if both systolic and diastolic values of blood pressure were below 1.64 SDS. The results from 2013 were juxtaposed with previously analyzed data from a similar study on hypertension in dialyzed children conducted in 2003/2004.
Results. Forty subjects have been provided with antihypertensive treatment. In monotherapy and polytherapy 50% of the subjects were treated with ACEI (enalapril and ramipril), 67.5% with amlodipine, 50% with beta-blockers. Only 10% of the subjects were treated with angiotensin II receptor blocker (losartan). Thirty percent of the subjects received furosemide, whereas 5% were given doxazosin. Antihypertensive drugs regarded as the 2nd and 3rd choice in treating high blood pressure (doxazosin, beta-blockers and furosemide) were applied as monotherapy in 46% of the patients. Satisfactory control of treated blood pressure was reached in 45% of them.
Conclusion. Antihypertensive treatment in dialyzed children did not change significantly during the last decade with regard to the groups of drugs being used. Despite a wider feasibility of antihypertensive substances, the effectiveness of this therapy was still unsatisfactory.

Key words

children, treatment, arterial hypertension, dialysis

References (34)

  1. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291–297.
  2. Agarwal R. Hypertension and survival in chronic hemodialysis patients – Past lessons and future opportunities. Kidney Int. 2005;67:1–13.
  3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
  4. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–502.
  5. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: Recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719–1742.
  6. Meyers RS, Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther. 2011;33:1331–1356.
  7. Kramer AM, van Stralen KJ, Jager KJ, et al. Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe. Kidney Int. 2011;80(10):1092–1098.
  8. Tkaczyk M, Nowicki M, Bałasz-Chmielewska I, et al. Hypertension in dialysed children: The prevalence and therapeutic approach in Poland – A nationwide survey. Nephrol Dial Transplant. 2006;21:736–742.
  9. Kułaga Z, Litwin M, Tkaczyk M, et al. Polish 2010 growth references for school-aged children and adolescents. Eur J Pediatr. 2011;170:599–609.
  10. Kułaga Z, Grajda A, Gurzkowska B, et al. Polish 2012 growth references for preschool children. Eur J Pediatr. 2013;172:753–761.
  11. Kułaga Z, Litwin M, Grajda A, et al. Oscillometric blood pressure percentiles for Polish normal-weight school-aged children and adolescents. J Hypertens. 2012;30:1942–1954.
  12. Mitsnefes M, Stablein D. Hypertension in pediatric patients on longterm dialysis: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Kidney Dis. 2005;45(2):309–315.
  13. Tsuruoka S, Kitoh Y, Kawaguchi A, et al. Clearance of imidapril, an angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: Comparison with quinapril and enalapril. J Clin Pharmacol. 2007;47(2):259–263.
  14. Wells T, Rippley R, Hogg R, et al. The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol. 2001;41:1064–1074.
  15. Seeman T, Dusek J, Vondrak K, Flogelova, Geier P, Janda J. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. Am J Hypertens. 2004;17:415–420.
  16. Wuhl E, Mehls O, Schaefer F, ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–776.
  17. Spagnolo A, Giussani M, Ambruzzi AM, et al. Focus on prevention, diagnosis and treatment of hypertension in children and adolescents. Ital J Pediatr. 2013;39:20. doi: 10.1186/1824-7288-39-20.
  18. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553.
  19. Flynn JT, Meyers KE, Neto JP, et al. Pediatric Valsartan Study Group. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1–5 years. Hypertension. 2008;52:222–228.
  20. Hörl MP, Hörl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial. 2004;17(4):288–294.
  21. Olyaei AJ, Bennett WM. Principles of drug usage in dialysis patients. In: Nissenson AR, Fine RN, eds. Handbook of Dialysis Therapy. 4th ed. Philadelphia, PA: Saunders Elsevier;2008:747–805.
  22. Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure. 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  23. Ibrahim RB, Liu C, Cronin SM, et al. Drug removal by plasmapheresis: An evidence-based review. Pharmacotherapy. 2007;27:1529–1549.
  24. Keller E, Reetze P, Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis: Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1990;18:104–117.
  25. Awdishu L, Bouchard J. How to optimize drug delivery in renal replacement therapy. Semin Dial. 2011;24(2):176–182.
  26. Weir MA, Dixon SN, Fleet JL, et al. β-blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol. 2015;26(4):987–996.
  27. Chaturvedi S, Lipszyc DH, Licht C, et al. Pharmacological interventions for hypertension in children. Evid Based Child Health. 2014;9(3):498–580.
  28. Blank SG, Mann SJ, James GD, et al. Isolated elevation of diastolic blood pressure. Real or artifactual? Hypertension. 1995;26:383–389.
  29. Wald R, Goldstein MB, Wald RM, et al. Correlates of left ventricular mass in chronic hemodialysis recipients. Int J Cardiovasc Imaging. 2014;30(2):349–356.
  30. Ferrario M, Moissl U, Garzotto F, et al. Effects of fluid overload on heart rate variability in chronic kidney disease patients on hemodialysis. BMC Nephrol. 2014;15:26.
  31. Di Iorio B, Di Micco L, Torraca S, et al. Variability of blood pressure in dialysis patients: A new marker of cardiovascular risk? J Nephrol. 2013;26(1):173–182.
  32. Wühl E, Trivelli A, Picca S, et al. ESCAPE Trial Group. Strict bloodpressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639–1650.
  33. Haskin O, Wong CJ, McCabe L, Begin B, Sutherland SM, Chaudhuri A. 44-h ambulatory blood pressure monitoring: Revealing the true burden of hypertension in pediatric hemodialysis patients. Pediatr Nephrol. 2015;30(4):653–660.
  34. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528–536.